<DOC>
	<DOCNO>NCT00344149</DOCNO>
	<brief_summary>Immune thrombocytopenic purpura ( ITP ) autoimmune disorder characterize thrombocytopenia . Splenectomy standard treatment patient fail first-line treatment : corticosteroid . Rituximab , recently emerge promising treatment ITP . The aim study determine whether early treatment Rituximab result durable remission , consequently , lead avoidance splenectomy significant number patient .</brief_summary>
	<brief_title>Rituximab Second Line Treatment ITP</brief_title>
	<detailed_description>ITP autoimmune disorder characterize formation autoantibody platelet antigen lead premature platelet destruction persistent thrombocytopenia often result bleed . The goal treatment raise platelet count hemostatically safe level . Treatment corticosteroid rarely result durable response , patient ultimately require second-line treatment . Splenectomy result high rate sustain remission . However , procedure invasive associate considerable short long term morbidity mortality . Rituximab , chimeric anti-CD20 antibody B-cell depleting effect , recently emerge promising treatment ITP . The study aim determine whether early treatment Rituximab result durable remission , consequently , avoidance splenectomy clinical significant number patient . The main objective study assess rate treatment failure ( splenectomy meeting criterion splenectomy week 12 ) 1.5-year prospective , randomize , placebo-controlled , double-blind , multi-centre</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . ITP platelet count &lt; 30 x 109 /l 2 week treatment prednisolon prednisolon taper period i.e . week three prednisolon initiation . Patients platelet count 30 50 eligible high platelet count consider necessary , : concomitant medical illness predispose bleeding ( hypertension , GI bleeding , bleed diathesis , previous history bleed ) concomitant medical condition require platelet block agents/ anticoagulation , persistent bleed despite platelet &gt; 30 x 109 /l , prior surgery , patient related factor necessitate high platelet count occupation , hobby , psychological intolerability . 2 . Subject &gt; 18 year 3 . Subject sign dated write informed consent . 4 . Subject able understand comply protocol requirement instruction , intend complete study plan . 5 . Females fertile age express willingness use contraceptive mean 6 month follow administration study drug . Exclusion criterion : 1 . Previous splenectomy , chemotherapy , treatment antiD Ig , rituximab , immunesuppressive treatment corticosteroid , Dapsone Danazol 2 . Underlying malignancy previous history malignancy past 5 year ( except skin carcinoma ) 3 . Pregnancy lactation 4 . Not willing participate study 5 . Expected survival &lt; 2 year 6 . Known intolerance murine antibodies 7 . Females childbearing age willing use contraception 6 month 8 . HIVpositive/AIDS , Hepatitis B virus positive Hepatitis C virus positive 9 . Patients definite Systemic Lupus Erythematosus ( SLE ) ( &gt; 4 American College Rheumatology Criteria ) 10 . Patients currently involve another clinical trial evaluation drug treatment 11 . Bacterial infection , viral infection , fungal infection , mycobacterial infection ( exclude fungal infection ) evolutive infection infection episode require hospitalisation treatment antibiotic 4 week selection IV route within 2 week selection oral route 12 . History soft tissue , bone joint infection ( fascitis , abscess , osteomyelitis , septic arthritis ) last year prior inclusion study 13 . Medical history relapse chronic severe infectious disease underlie pathology predispose serious infection 14 . Known Primary secondary immune deficiency syndromes 15 . Administration live vaccine within 4 week precede inclusion study 16 Previous treatment lymphocytes deplete medication ( e.g . : MabCampath® ) 17 Previous treatment inhibitor leucocytes transmigration ( e.g . : Tysabri® ) 18 Known intolerance human monoclonal antibody 19 Known severe chronic pulmonary obstructive Disease ( FEV &lt; 50 % functional dyspnoea grade 3 ) 20 Known congestive heart failure NYHA ( New York Heart Association classification heart failure ) class III IV 21 Recent episode ( &lt; 6 month ) acute coronary syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Splenectomy</keyword>
	<keyword>Response</keyword>
	<keyword>Treatment</keyword>
	<keyword>treatment Idiopathic Thrombocytopenic Purpura</keyword>
</DOC>